Molecular Biology Reports

, Volume 39, Issue 2, pp 1863–1868 | Cite as

Association between C1431T polymorphism in peroxisome proliferator-activated receptor-γ gene and coronary artery disease in Chinese Han population

  • Xiang Zhou
  • Jianchang Chen
  • Weiting XuEmail author


The C1431T polymorphism in peroxisome proliferator-activated receptor-γ (PPARγ) has been shown to be associated with diabetes, obesity, and metabolic syndrome. However, it is unclear whether this polymorphism is associated with coronary artery disease (CAD). Therefore, we conducted a hospital-based case–control study with 864 CAD patients and 1008 controls to explore the association between the PPARγ C1431T polymorphism and risk of CAD in Chinese Han population. Subjects with the variant genotypes (CT + TT) had a 39% decreased risk of CAD relative to CC carriers (adjusted odds ratio, 0.61; 95% confidence interval, 0.49–0.76). Our results suggested that the C1431T polymorphism was associated with a higher body mass index in both CAD patients and controls. Moreover, this polymorphism was also found to be associated with a higher HDL cholesterol level and a lower blood glucose level in CAD patients. In stratified analyses, the T allele was significantly associated with reduced risk of CAD in males, subjects with age <62 years, and non-smokers. In conclusion, the PPARγ C1431T polymorphism is associated with decreased risk of CAD in Chinese Han population.


Peroxisome proliferator-activated receptor-γ Polymorphism Coronary artery disease Angiography 



This study was supported by Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University.


  1. 1.
    Issemann I, Green S (1999) Activation of a number of the steroid receptor superfamily by peroxisome. Nature 347:645–650CrossRefGoogle Scholar
  2. 2.
    Varga T, Nagy L (2008) Nuclear receptors, transcription factors linking lipid metabolism and immunity: the case of peroxisome proliferator-activated receptor gamma. Eur J Clin Invest 38:695–707PubMedCrossRefGoogle Scholar
  3. 3.
    Beamer BA, Negri C, Yen CJ et al (1997) Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun 233:756–759PubMedCrossRefGoogle Scholar
  4. 4.
    Fajas L, Auboeuf D, Raspé E et al (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779–18789PubMedCrossRefGoogle Scholar
  5. 5.
    Fajas L, Fruchart JC, Auwerx J (1998) PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 438:55–60PubMedCrossRefGoogle Scholar
  6. 6.
    Sundvold H, Lien S (2001) Identification of a novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem Biophys Res Commun 287:383–390PubMedCrossRefGoogle Scholar
  7. 7.
    Vigouroux C, Fajas L, Khallouf E et al (1998) Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 47:490–492PubMedCrossRefGoogle Scholar
  8. 8.
    Deeb SS, Fajas L, Nemoto M et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287PubMedCrossRefGoogle Scholar
  9. 9.
    Savage DB, Tan GD, Acerini CL et al (2003) Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma. Diabetes 52:910–917PubMedCrossRefGoogle Scholar
  10. 10.
    Zaman AG, Helft G, Worthley SG, Badimon JJ (2000) The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149:251–266PubMedCrossRefGoogle Scholar
  11. 11.
    Marx N, Sukhova GM, Murphy C, Libby P, Plutzky J (1998) Macrophages in human atheroma contain PPARgamma: Differentiation-dependent PPARgamma expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 153:17–23PubMedCrossRefGoogle Scholar
  12. 12.
    Buzzetti R, Petrone A, Caiazzo AM et al (2005) PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity in childhood obesity. Pediatr Res 57:138–140PubMedCrossRefGoogle Scholar
  13. 13.
    Moffett SP, Feingold E, Barmada MM et al (2005) The C161–>T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in peroxisome proliferator-activated receptor gamma. Metabolism 54:1552–1556PubMedCrossRefGoogle Scholar
  14. 14.
    Tai ES, Corella D, Deurenberg-Yap M et al (2004) Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res 45:485–674CrossRefGoogle Scholar
  15. 15.
    Wang XL, Oosterhof J, Duarte N (1999) Peroxisome proliferator-activated receptor gamma C161 → T polymorphism and coronary artery disease. Cardiovasc Res 44:588–594PubMedCrossRefGoogle Scholar
  16. 16.
    Doney AS, Fischer B, Leese G, Morris AD, Palmer CN (2004) Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 24:2403–2407PubMedCrossRefGoogle Scholar
  17. 17.
    Santamore WP, Kahl FR, Kutcher MA et al (1988) A microcomputer based automated, quantitative coronary angiographic analysis system. Ann Biomed Eng 16:367–377PubMedCrossRefGoogle Scholar
  18. 18.
    Favis R, Day JP, Gerry NP et al (2000) Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2. Nat Biotechnol 18:561–564PubMedCrossRefGoogle Scholar
  19. 19.
    Xiao Z, Xiao J, Jiang Y et al (2006) A novel method based on ligase detection reaction for low abundant YIDD mutants detection in hepatitis B virus. Hepatol Res 34:150–155PubMedCrossRefGoogle Scholar
  20. 20.
    Sanada K, Iemitsu M, Murakami H et al (2011) PPARγ2 C1431T genotype increases metabolic syndrome risk in young men with low cardiorespiratory fitness. Physiol Genom 43:103–109CrossRefGoogle Scholar
  21. 21.
    Lagou V, Scott RA, Manios Y et al (2008) Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS study. Obesity (Silver Spring) 16:913–918CrossRefGoogle Scholar
  22. 22.
    Yang LL, Hua Q, Liu RK, Yang Z (2009) Association between two common polymorphisms of PPARgamma gene and metabolic syndrome families in a Chinese population. Arch Med Res 40:89–96PubMedCrossRefGoogle Scholar
  23. 23.
    Doney A, Fischer B, Frew D et al (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21PubMedCrossRefGoogle Scholar
  24. 24.
    Parmley WW (1989) Prevalence and clinical significance of silent myocardial ischemia. Circulation 80:IV68–IV73PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of CardiologyThe Second Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations